背景(考古学)
髓系白血病
医学
生活质量(医疗保健)
重症监护医学
内科学
护理部
古生物学
生物
作者
Adriano Venditti,Raffaele Palmieri,Luca Maurillo,Christoph Röllig,Agnieszka Wierzbowska,David C. de Leeuw,Fabio Efficace,Antonio Curti,Lok Lam Ngai,Jesse M. Tettero,Lionel Adès,António Almeida,Lars Bullinger,Mike Dennis,Jordi Esteve,Felicetto Ferrara,Michael Heuser,Gerwin Huls,Michael Lübbert,Priyanka Mehta
标识
DOI:10.1182/bloodadvances.2024013744
摘要
Fitness assessment in patients with acute myeloid leukemia (AML) is critical to deliver the right therapy to the right patient. While several scoring systems are available to aid in determining fitness, the absence of validation studies has resulted in the lack of universally accepted assessment procedures. This limitation, combined with the increasing availability of novel agents expanding the spectrum of less-intensive options, has introduced additional complexity to the fitness assessment process. In this evolving context, fitness should reflect eligibility for a specific treatment among the several available, rather than a generic binary classification of eligibility for intensive chemotherapy. Moreover, the growing emphasis on patient-centered care, further highlights the importance of integrating quality of life, patients' preferences, patients' self-reported physical and social functioning status, social support, and early integration of palliative care into the assessment framework. A modern interpretation of fitness assessment should incorporate a comprehensive evaluation that extends beyond traditional clinical and biological disease characteristics. Thus, fitness assessment in patients with AML represents only one piece of a larger puzzle, encompassing the patient's overall capacity to sustain and benefit from a specific therapeutic program.
科研通智能强力驱动
Strongly Powered by AbleSci AI